Please fill out the short form to register for all four webinars.
Part 1: Adding CNVs and fusions to a lung cfDNA assay: impact on oncology clinical research
Speakers:
Beatriz Bellosillo, PhD, Head of Pathology, Hospital del Mar, Spain
Kelli Bramlett, PhD, Senior Director of R&D for Clinical Next-Generation Sequencing at Thermo Fisher Scientific
Abstract:
Dr. Bellosillo discusses her experience evaluating an early-access lung cancer panel that detects copy number variants (CNVs) and fusions. Following her talk, Dr. Bramlett presents a new white paper that showcases the performance of the new variant types introduced in the Ion Torrent Oncomine Lung cfDNA Assay that Dr. Bellosillo evaluated.
Part 2: Evaluation of a pan-cancer cell-free assay to meet unmet research needs
Speaker:
Luca Quagliata, PhD, Senior Consultant, R&D Unit, Molecular Pathology Unit University Hospital Basel, Institute for Medical Genetics and Pathology
Abstract:
Dr. Quagliata shares two specific unmet needs within his lab’s research that led to the eventual evaluation, adoption, and implementation of the latest Ion Torrent Oncomine NGS solutions for liquid biopsy.
Part 3: From qualitative to quantitative: experiences with a cfDNA assay in metastatic breast cancer
Speaker:
Liya Xu, PhD, Postdoctoral Scholar, Kuhn/Hicks Laboratory, USC Michelson Center for Convergent Bioscience
Abstract:
Dr. Liya Xu discusses her team’s work using liquid biopsy technology for breast cancer research. Data is presented from liquid biopsy research samples from metastatic breast cancer, demonstrating integration of analytical variables of cfDNA samples obtained from the Ion Torrent Oncomine Breast cfDNA assay v2 and genomic analysis and protein marker data from single circulating tumor cells.
Part 4: Non-invasive characterization of solid tumors via NGS liquid biopsy testing
Speaker:
Gorka Alkorta-Aranburu, PhD, Co-Director, Solid Tumor and Constitutional Disease Diagnostic Laboratory, University of Navarra (UNAV), Pamplona, Spain
Abstract:
Dr. Alkorta-Aranburu will review how liquid biopsy can be considered as an alternative and non-invasive method to tissue biopsy for cancer molecular characterization. Liquid biopsy allows the study of tumor-specific circulating components including circulating tumor cells (CTCs), circulating cell-free tumor DNA (ctDNA) and RNA (ctRNA). The potentials and challenges of this new approach and its impact on precision medicine will be discussed.
